Why Was the Azithromycin “for Life” Trial Necessary?
New England Journal of Medicine · 2024
DOI: 10.1056/nejme2407000 ↗Kurz gefasst
Editorial in der Zeitschrift New England Journal of Medicine, 2024. Verfasst von Kathryn Maitland und 1 weiteren Autor:innen. Beteiligte Einrichtung: From the Department of Infectious Disease and Institute of Global Health and Innovation, Division of Medicine, Imperial College (K.M.), and the Medic…. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Azithromycin, Mass Drug Administration, Bacterial Infections. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 10 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- From the Department of Infectious Disease and Institute of Global Health and Innovation, Division of Medicine, Imperial College (K.M.), and the Medical Research Council Clinical Trials Unit, University College London (A…
ORCID-Profile: Kathryn Maitland, A Sarah Walker
Zitieren
APA
Maitland, K., & Walker, A. S. (2024). Why Was the Azithromycin “for Life” Trial Necessary?. New England Journal of Medicine. https://doi.org/10.1056/nejme2407000
Vancouver
Maitland K, Walker AS. Why Was the Azithromycin “for Life” Trial Necessary?. New England Journal of Medicine. 2024. doi:10.1056/nejme2407000
BibTeX
@article{Maitland2024,
author = {Maitland, Kathryn and Walker, A Sarah},
title = {Why Was the Azithromycin “for Life” Trial Necessary?},
journal = {New England Journal of Medicine},
year = {2024},
doi = {10.1056/nejme2407000}
}
EUVIMED